181 related articles for article (PubMed ID: 23856321)
1. Luminescent multiplex viability assay for Trypanosoma brucei gambiense.
Van Reet N; Pyana P; Rogé S; Claes F; Büscher P
Parasit Vectors; 2013 Jul; 6():207. PubMed ID: 23856321
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
3. A panel of Trypanosoma brucei strains tagged with blue and red-shifted luciferases for bioluminescent imaging in murine infection models.
Van Reet N; Van de Vyver H; Pyana PP; Van der Linden AM; Büscher P
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3054. PubMed ID: 25144573
[TBL] [Abstract][Full Text] [Related]
4. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.
Graf FE; Baker N; Munday JC; de Koning HP; Horn D; Mäser P
Int J Parasitol Drugs Drug Resist; 2015 Aug; 5(2):65-8. PubMed ID: 26042196
[TBL] [Abstract][Full Text] [Related]
5. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
Graf FE; Ludin P; Wenzler T; Kaiser M; Brun R; Pyana PP; Büscher P; de Koning HP; Horn D; Mäser P
PLoS Negl Trop Dis; 2013; 7(10):e2475. PubMed ID: 24130910
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for second-stage human African trypanosomiasis.
Lutje V; Seixas J; Kennedy A
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for second-stage Human African trypanosomiasis.
Lutje V; Seixas J; Kennedy A
Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Betu Kumeso VK; Kalonji WM; Rembry S; Valverde Mordt O; Ngolo Tete D; Prêtre A; Delhomme S; Ilunga Wa Kyhi M; Camara M; Catusse J; Schneitter S; Nusbaumer M; Mwamba Miaka E; Mahenzi Mbembo H; Makaya Mayawula J; Layba Camara M; Akwaso Massa F; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Mutanda Kalonji S; Mariero Philemon P; Mokilifi Nganyonyi R; Embana Mankiara H; Asuka Akongo Nguba A; Kobo Muanza V; Mulenge Nasandhel E; Fifi Nzeza Bambuwu A; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Infect Dis; 2023 Apr; 23(4):463-470. PubMed ID: 36460027
[TBL] [Abstract][Full Text] [Related]
10. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
Maina N; Maina KJ; Mäser P; Brun R
Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
[TBL] [Abstract][Full Text] [Related]
11. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
12. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo.
Pyana PP; Sere M; Kaboré J; De Meeûs T; MacLeod A; Bucheton B; Van Reet N; Büscher P; Belem AMG; Jamonneau V
Infect Genet Evol; 2015 Mar; 30():128-133. PubMed ID: 25535944
[TBL] [Abstract][Full Text] [Related]
13. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
[TBL] [Abstract][Full Text] [Related]
14. The phenomenon of treatment failures in Human African Trypanosomiasis.
Brun R; Schumacher R; Schmid C; Kunz C; Burri C
Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
[TBL] [Abstract][Full Text] [Related]
15. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.
Sykes ML; Baell JB; Kaiser M; Chatelain E; Moawad SR; Ganame D; Ioset JR; Avery VM
PLoS Negl Trop Dis; 2012; 6(11):e1896. PubMed ID: 23209849
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004.
Likeufack AC; Brun R; Fomena A; Truc P
Acta Trop; 2006 Nov; 100(1-2):11-6. PubMed ID: 17078916
[TBL] [Abstract][Full Text] [Related]
17. Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1.
Capewell P; Veitch NJ; Turner CM; Raper J; Berriman M; Hajduk SL; MacLeod A
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1287. PubMed ID: 21909441
[TBL] [Abstract][Full Text] [Related]
18. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis.
Babokhov P; Sanyaolu AO; Oyibo WA; Fagbenro-Beyioku AF; Iriemenam NC
Pathog Glob Health; 2013 Jul; 107(5):242-52. PubMed ID: 23916333
[TBL] [Abstract][Full Text] [Related]
19. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
[TBL] [Abstract][Full Text] [Related]
20. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
Iten M; Matovu E; Brun R; Kaminsky R
Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
